Amberen Review: 3 Real Facts Including an FTC Injunction

The FTC filed a permanent injunction against Amberen’s original marketer, Lunada Biomedical, in 2015 over specific claims that the supplement causes weight and belly fat loss in menopausal women — a real regulatory action worth knowing about a product now owned by a $110 million acquirer. This Amberen review checked what survived that scrutiny.

How We Researched This Amberen Review

This Amberen review checked the actual FTC complaint and injunction against Lunada Biomedical, the published clinical research behind succinate-based ingredients, and the brand’s ownership history through its 2020 acquisition.

Amberen Review: What Is It?

Originally developed at Russia’s Institute of Theoretical and Experimental Biophysics, Amberen is a hormone-free, drug-free menopause supplement built around ammonium succinate, calcium disuccinate, and magnesium disuccinate, marketed to relieve up to 12 menopause symptoms including hot flashes, mood swings, weight gain, and night sweats. US marketing rights moved to Lunada Biomedical in 2006, then to Biogix as its flagship product; Alliance Pharma plc acquired Biogix for $110 million in 2020.

What the Research on Succinate Ingredients Shows

• Advanced Gerontology: 2008 research on mice found succinate therapy reduced menopause symptoms.
• Obstetrics and Gynecology International: more recent 2019 research supports those earlier conclusions.
• Nutrients: while no direct research exists on magnesium disuccinate specifically, magnesium generally shows evidence for reducing stress-related symptoms.

The 2015 FTC Action Against the Original Marketer

This is genuinely important context: the FTC filed a permanent injunction and monetary judgment against Lunada Biomedical in 2015, specifically citing Amberen’s labeling and marketing — particularly claims that it causes weight and belly fat loss in menopausal and perimenopausal women. This predates the current ownership under Alliance Pharma, but the underlying product and core claims trace directly back to that scrutinized marketing.

What the Actual Clinical Study Found

A 3-month study of 125 women aged 42-60, published in Gynecology and Endocrinology, found Amberen users experienced relief in 13 of 21 tracked menopause symptoms — a genuine, specific clinical result. Notably, this study focused on general menopause symptom relief; the weight/belly-fat-specific claims were the ones the FTC action targeted.

Who Should Know About the Manufacturer History

Lunada Biomedical (Los Angeles) isn’t BBB-accredited, and the BBB has had documented difficulty even reaching the company for contact verification — worth noting, though this refers to the original marketer rather than current owner Alliance Pharma.

Does Amberen Work?

The core succinate-based formula has genuine research support for general menopause symptom relief, backed by a real clinical study. The specific weight-loss and belly-fat claims are the ones that drew FTC scrutiny — worth separating from the more broadly supported symptom-relief claims when evaluating this product.

Who Amberen Actually Makes Sense For

This fits menopausal or perimenopausal women seeking symptom relief (hot flashes, mood, sleep) specifically, based on the genuine clinical study behind the formula. It’s a poor fit for anyone buying it specifically for the weight-loss or belly-fat claims — those were the exact claims the FTC found problematic.

Frequently Asked Questions

The Bottom Line

Amberen’s succinate-based formula has genuine clinical research support for general menopause symptom relief, but the specific weight-loss and belly-fat claims were the subject of a 2015 FTC injunction against its original marketer. This Amberen review found a reasonably evidence-backed symptom-relief supplement best evaluated separately from its more contested weight-loss marketing.

Explore more Weight Loss Program reviews and guides on our site.